{
  "source": "nccn-breast",
  "version": "1.2025",
  "description": "Gold set for NCCN Breast Cancer Guidelines ctDNA/MRD recommendations",
  "expectedExtractions": [
    {
      "id": "nccn-breast-surveillance-1",
      "type": "recommendation",
      "cancerType": "breast",
      "clinicalSetting": "surveillance",
      "evidenceLevel": "Category 2A",
      "keyQuote": "ctDNA testing for surveillance after curative therapy",
      "mustContain": ["ctDNA", "surveillance", "breast"],
      "mustNotContain": ["treatment selection"]
    },
    {
      "id": "nccn-breast-mrd-1",
      "type": "recommendation",
      "cancerType": "breast",
      "clinicalSetting": "post_treatment",
      "evidenceLevel": "Category 2A",
      "keyQuote": "MRD detection after neoadjuvant therapy",
      "mustContain": ["MRD", "neoadjuvant", "breast"],
      "mustNotContain": []
    },
    {
      "id": "nccn-breast-tnbc-1",
      "type": "recommendation",
      "cancerType": "breast",
      "clinicalSetting": "adjuvant",
      "evidenceLevel": "Category 2B",
      "keyQuote": "triple-negative breast cancer adjuvant decisions",
      "mustContain": ["triple-negative", "adjuvant"],
      "mustNotContain": []
    }
  ],
  "metadata": {
    "createdAt": "2026-02-02",
    "createdBy": "claude",
    "totalExpectedItems": 3,
    "targetAccuracy": 0.8
  }
}
